Ibnsina Pharma (CAI:ISPH) Cash Flow for Dividends: E£-198 Mil (TTM As of Mar. 2026)


CAI:ISPH Ibnsina Pharma CAI:ISPH
85 GF Score
Price E£11.60
GF Value E£10.48
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ibnsina Pharma Cash Flow for Dividends?

Ibnsina Pharma CAI:ISPH -0.60% 85 Cash Flow for Dividends is E£-198 Mil as of Mar. 2026. GuruFocus rates CAI:ISPH with a GF Score™ of 85/100 and a GF Value™ of E£10.48 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Ibnsina Pharma's cash flow for dividends for the three months ended in Mar. 2026 was E£0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was E£-198 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Ibnsina Pharma's quarterly payment of dividends increased from Sep. 2025 (E£-7 Mil) to Dec. 2025 (E£-161 Mil) but then declined from Dec. 2025 (E£-161 Mil) to Mar. 2026 (E£0 Mil).

Ibnsina Pharma's annual payment of dividends increased from Dec. 2023 (E£-23 Mil) to Dec. 2024 (E£-26 Mil) and increased from Dec. 2024 (E£-26 Mil) to Dec. 2025 (E£-201 Mil).

Ibnsina Pharma Cash Flow for Dividends Related Terms

Ibnsina Pharma Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Ibnsina Pharma's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ibnsina Pharma Cash Flow for Dividends Chart

Ibnsina Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -140.40 -22.94 -25.62 -201.04

Ibnsina Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.47 -29.34 -6.95 -161.28 0.00
CAI:ISPH
85GF Score
Ibnsina Pharma CAI:ISPH
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ibnsina Pharma Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-198 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of E£-198 Mil mean?
Ibnsina Pharma (CAI:ISPH) has a Cash Flow for Dividends of E£-198 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Ibnsina Pharma and its competitors.
Is Ibnsina Pharma's Cash Flow for Dividends too high?
Ibnsina Pharma's current Cash Flow for Dividends is E£-198 Mil. Overall, Ibnsina Pharma has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Cash Flow for Dividends compare to MCK and CAH?
Ibnsina Pharma's Cash Flow for Dividends of E£-198 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Distribution company?
A good Cash Flow for Dividends depends on the Medical Distribution industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Ibnsina Pharma and its competitors. Ibnsina Pharma's current Cash Flow for Dividends is E£-198 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.48, compared to a current price of E£11.60 — trading 10.7% above its estimated fair value. The current Cash Flow for Dividends is E£-198 Mil. Ibnsina Pharma's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Cash Flow for Dividends is E£-198 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?

Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued. The current stock price of E£11.60 is trading 10.7% above its estimated GF Value™ of E£10.48. GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.

Key valuation signals for CAI:ISPH:

  • Cash Flow for Dividends: E£-198 Mil
  • GF Value™: E£10.48 vs. price of E£11.60 (10.7% above fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ibnsina Pharma Business Description

Address Industrial zone 1, PO box 91, Obour, EGY
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
85GF Score

Get the complete analysis for CAI:ISPH

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£11.60
Price
E£10.48
GF Value